SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
